{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:48:13Z","timestamp":1790916493921,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Abeome Corporation \/ Lanier Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>IL-25 is implicated in the pathogenesis of viral asthma exacerbations. However, the effect of IL-25 on antiviral immunity has yet to be elucidated. We observed abundant expression and colocalization of IL-25 and IL-25 receptor at the apical surface of uninfected airway epithelial cells and rhinovirus infection increased IL-25 expression. Analysis of immune transcriptome of rhinovirus-infected differentiated asthmatic bronchial epithelial cells (BECs) treated with an anti-IL-25 monoclonal antibody (LNR125) revealed a re-calibrated response defined by increased type I\/III IFN and reduced expression of type-2 immune genes CCL26, IL1RL1 and IL-25 receptor. LNR125 treatment also increased type I\/III IFN expression by coronavirus infected BECs. Exogenous IL-25 treatment increased viral load with suppressed innate immunity. In vivo LNR125 treatment reduced IL-25\/type 2 cytokine expression and increased IFN-\u03b2 expression and reduced lung viral load. We define a new immune-regulatory role for IL-25 that directly inhibits virus induced airway epithelial cell innate anti-viral immunity.<\/jats:p>","DOI":"10.1038\/s42003-022-03367-z","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T10:04:21Z","timestamp":1651658661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["IL-25 blockade augments antiviral immunity during respiratory virus infection"],"prefix":"10.1038","volume":"5","author":[{"given":"Teresa C.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Ling","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy S.","family":"Nichol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1612-0907","authenticated-orcid":false,"given":"Punnam C.","family":"Veerati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Esneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-6126","authenticated-orcid":false,"given":"Peter A. B.","family":"Wark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Grainge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl A.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal L.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirby","family":"Alton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Shimkets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0739-1070","authenticated-orcid":false,"given":"Jason L.","family":"Girkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2715-5163","authenticated-orcid":false,"given":"Nathan W.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"3367_CR1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1164\/ajrccm.154.3.8810601","volume":"154","author":"SL Johnston","year":"1996","unstructured":"Johnston, S. L. et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am. J. Respir. Crit. Care Med. 154, 654\u2013660 (1996).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"3367_CR2","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1136\/bmj.307.6910.982","volume":"307","author":"KG Nicholson","year":"1993","unstructured":"Nicholson, K. G., Kent, J. & Ireland, D. C. Respiratory viruses and exacerbations of asthma in adults. Bmj 307, 982\u2013986 (1993).","journal-title":"Bmj"},{"key":"3367_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/17476348.2016.1180249","volume":"10","author":"H Tay","year":"2016","unstructured":"Tay, H., Wark, P. A. & Bartlett, N. W. Advances in the treatment of virus-induced asthma. Expert Rev. Respir. Med. 10, 629\u2013641 (2016).","journal-title":"Expert Rev. Respir. Med"},{"key":"3367_CR4","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nm.2768","volume":"18","author":"PG Holt","year":"2012","unstructured":"Holt, P. G. & Sly, P. D. Viral infections and atopy in asthma pathogenesis: new rationales for asthma prevention and treatment. Nat. Med 18, 726\u2013735 (2012).","journal-title":"Nat. Med"},{"key":"3367_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3786","volume":"15","author":"JV Fahy","year":"2015","unstructured":"Fahy, J. V. Type 2 inflammation in asthma\u2013present in most, absent in many. Nat. Rev. Immunol. 15, 57\u201365 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"3367_CR6","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","volume":"368","author":"S Wenzel","year":"2013","unstructured":"Wenzel, S. et al. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 368, 2455\u20132466 (2013).","journal-title":"N. Engl. J. Med"},{"key":"3367_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","volume":"2","author":"M Castro","year":"2014","unstructured":"Castro, M. et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Med. 2, 879\u2013890 (2014).","journal-title":"Lancet Respiratory Med."},{"key":"3367_CR8","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa0808991","volume":"360","author":"P Haldar","year":"2009","unstructured":"Haldar, P. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med 360, 973\u2013984 (2009).","journal-title":"N. Engl. J. Med"},{"key":"3367_CR9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1183\/09031936.00223411","volume":"41","author":"E Piper","year":"2013","unstructured":"Piper, E. et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur. Respir. J. 41, 330\u2013338 (2013).","journal-title":"Eur. Respir. J."},{"key":"3367_CR10","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega, H. G. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198\u20131207 (2014).","journal-title":"N. Engl. J. Med"},{"key":"3367_CR11","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","volume":"184","author":"M Castro","year":"2011","unstructured":"Castro, M. et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 184, 1125\u20131132 (2011).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"3367_CR12","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","volume":"70","author":"NA Hanania","year":"2015","unstructured":"Hanania, N. A. et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70, 748\u2013756 (2015).","journal-title":"Thorax"},{"key":"3367_CR13","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1704064","volume":"377","author":"J Corren","year":"2017","unstructured":"Corren, J. et al. Tezepelumab in Adults with Uncontrolled Asthma. N. Engl. J. Med. 377, 936\u2013946 (2017).","journal-title":"N. Engl. J. Med"},{"key":"3367_CR14","doi-asserted-by":"publisher","first-page":"256ra134","DOI":"10.1126\/scitranslmed.3009124","volume":"6","author":"J Beale","year":"2014","unstructured":"Beale, J. et al. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci. Transl. Med. 6, 256ra134 (2014).","journal-title":"Sci. Transl. Med"},{"key":"3367_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaci.2011.03.043","volume":"128","author":"CJ Corrigan","year":"2011","unstructured":"Corrigan, C. J. et al. Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses. J. Allergy Clin. Immunol. 128, 116\u2013124 (2011).","journal-title":"J. Allergy Clin. Immunol."},{"key":"3367_CR16","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1084\/jem.20051615","volume":"203","author":"PG Fallon","year":"2006","unstructured":"Fallon, P. G. et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J. Exp. Med 203, 1105\u20131116 (2006).","journal-title":"J. Exp. Med"},{"key":"3367_CR17","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/j.1365-2222.2010.03542.x","volume":"40","author":"H Wang","year":"2010","unstructured":"Wang, H. et al. Allergen challenge of peripheral blood mononuclear cells from patients with seasonal allergic rhinitis increases IL-17RB, which regulates basophil apoptosis and degranulation. Clin. Exp. Allergy 40, 1194\u20131202 (2010).","journal-title":"Clin. Exp. Allergy"},{"key":"3367_CR18","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1073\/pnas.1014241108","volume":"108","author":"CJ Corrigan","year":"2011","unstructured":"Corrigan, C. J. et al. T-helper cell type 2 (Th2) memory T cell-potentiating cytokine IL-25 has the potential to promote angiogenesis in asthma. Proc. Natl Acad. Sci. USA 108, 1579\u20131584 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3367_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1165\/rcmb.2012-0304OC","volume":"49","author":"H Kouzaki","year":"2013","unstructured":"Kouzaki, H., Tojima, I., Kita, H. & Shimizu, T. Transcription of interleukin-25 and extracellular release of the protein is regulated by allergen proteases in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 49, 741\u2013750 (2013).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"3367_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1128\/CMR.00014-10","volume":"24","author":"M Vareille","year":"2011","unstructured":"Vareille, M., Kieninger, E., Edwards, M. R. & Regamey, N. The airway epithelium: soldier in the fight against respiratory viruses. Clin. Microbiol Rev. 24, 210\u2013229 (2011).","journal-title":"Clin. Microbiol Rev."},{"key":"3367_CR21","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1128\/JVI.80.9.4501-4509.2006","volume":"80","author":"N Ank","year":"2006","unstructured":"Ank, N. et al. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 80, 4501\u20134509 (2006).","journal-title":"J. Virol."},{"key":"3367_CR22","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/intimm\/dxh318","volume":"17","author":"K Honda","year":"2005","unstructured":"Honda, K., Yanai, H., Takaoka, A. & Taniguchi, T. Regulation of the type I IFN induction: a current view. Int Immunol. 17, 1367\u20131378 (2005).","journal-title":"Int Immunol."},{"key":"3367_CR23","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1084\/jem.20041901","volume":"201","author":"PA Wark","year":"2005","unstructured":"Wark, P. A. et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J. Exp. Med 201, 937\u2013947 (2005).","journal-title":"J. Exp. Med"},{"key":"3367_CR24","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nm1462","volume":"12","author":"M Contoli","year":"2006","unstructured":"Contoli, M. et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat. Med 12, 1023\u20131026 (2006).","journal-title":"Nat. Med"},{"key":"3367_CR25","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fimmu.2020.00974","volume":"11","author":"PC Veerati","year":"2020","unstructured":"Veerati, P. C. et al. Airway Epithelial Cell Immunity Is Delayed During Rhinovirus Infection in Asthma and COPD. Front Immunol. 11, 974 (2020).","journal-title":"Front Immunol."},{"key":"3367_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nm1713","volume":"14","author":"NW Bartlett","year":"2008","unstructured":"Bartlett, N. W. et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat. Med 14, 199\u2013204 (2008).","journal-title":"Nat. Med"},{"key":"3367_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17952-4","volume":"7","author":"KM Martinovich","year":"2017","unstructured":"Martinovich, K. M. et al. Conditionally reprogrammed primary airway epithelial cells maintain morphology, lineage and disease specific functional characteristics. Sci. Rep. 7, 17971 (2017).","journal-title":"Sci. Rep."},{"key":"3367_CR28","doi-asserted-by":"crossref","unstructured":"Girkin, J. et al. TLR2-mediated innate immune priming boosts lung anti-viral immunity. Eur. Respir. J. 58, 2001584 (2020).","DOI":"10.1183\/13993003.01584-2020"},{"key":"3367_CR29","doi-asserted-by":"publisher","first-page":"L926","DOI":"10.1152\/ajplung.00374.2020","volume":"319","author":"SL Loo","year":"2020","unstructured":"Loo, S. L. et al. Human coronaviruses 229E and OC43 replicate and induce distinct antiviral responses in differentiated primary human bronchial epithelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 319, L926\u2013L931 (2020).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"3367_CR30","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1189\/jlb.0913482","volume":"95","author":"BC Petersen","year":"2014","unstructured":"Petersen, B. C., Dolgachev, V., Rasky, A. & Lukacs, N. W. IL-17E (IL-25) and IL-17RB promote respiratory syncytial virus-induced pulmonary disease. J. Leukoc. Biol. 95, 809\u2013815 (2014).","journal-title":"J. Leukoc. Biol."},{"key":"3367_CR31","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jaci.2006.04.051","volume":"118","author":"T Tamachi","year":"2006","unstructured":"Tamachi, T. et al. IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice. J. Allergy Clin. Immunol. 118, 606\u2013614 (2006).","journal-title":"J. Allergy Clin. Immunol."},{"key":"3367_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaci.2011.09.041","volume":"129","author":"JL Barlow","year":"2012","unstructured":"Barlow, J. L. et al. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J. Allergy Clin. Immunol. 129, 191\u2013198 e191-194 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"3367_CR33","doi-asserted-by":"crossref","unstructured":"Chairakaki, A. D. et al. Plasmacytoid dendritic cells drive acute asthma exacerbations. J. Allergy Clin. Immunol. 142, 542\u2013556.e12 (2017).","DOI":"10.1016\/j.jaci.2017.08.032"},{"key":"3367_CR34","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.2147\/JIR.S304320","volume":"14","author":"H Hong","year":"2021","unstructured":"Hong, H. et al. Induction of IL-25 Expression in Human Nasal Polyp Epithelium by Influenza Virus Infection is Abated by Interferon-Alpha Pretreatment. J. Inflamm. Res. 14, 2769\u20132780 (2021).","journal-title":"J. Inflamm. Res"},{"key":"3367_CR35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nri3831","volume":"15","author":"TA Wynn","year":"2015","unstructured":"Wynn, T. A. Type 2 cytokines: mechanisms and therapeutic strategies. Nat. Rev. Immunol. 15, 271\u2013282 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"3367_CR36","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/mi.2017.77","volume":"11","author":"L Denney","year":"2018","unstructured":"Denney, L., Branchett, W., Gregory, L. G., Oliver, R. A. & Lloyd, C. M. Epithelial-derived TGF-beta1 acts as a pro-viral factor in the lung during influenza A infection. Mucosal Immunol. 11, 523\u2013535 (2018).","journal-title":"Mucosal Immunol."},{"key":"3367_CR37","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jaci.2012.05.023","volume":"130","author":"SR Durrani","year":"2012","unstructured":"Durrani, S. R. et al. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J. Allergy Clin. Immunol. 130, 489\u2013495 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"3367_CR38","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/thoraxjnl-2014-205465","volume":"70","author":"L Hatchwell","year":"2015","unstructured":"Hatchwell, L. et al. Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia. Thorax 70, 854\u2013861 (2015).","journal-title":"Thorax"},{"key":"3367_CR39","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1165\/rcmb.2005-0034OC","volume":"33","author":"CK Wong","year":"2005","unstructured":"Wong, C. K., Cheung, P. F., Ip, W. K. & Lam, C. W. Interleukin-25-induced chemokines and interleukin-6 release from eosinophils is mediated by p38 mitogen-activated protein kinase, c-Jun N-terminal kinase, and nuclear factor-kappaB. Am. J. Respir. Cell Mol. Biol. 33, 186\u2013194 (2005).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"3367_CR40","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.4049\/jimmunol.1402760","volume":"194","author":"L Wu","year":"2015","unstructured":"Wu, L. et al. A novel IL-25 signaling pathway through STAT5. J. Immunol. 194, 4528\u20134534 (2015).","journal-title":"J. Immunol."},{"key":"3367_CR41","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.cub.2005.08.036","volume":"15","author":"C Wellbrock","year":"2005","unstructured":"Wellbrock, C. et al. STAT5 contributes to interferon resistance of melanoma cells. Curr. Biol. 15, 1629\u20131639 (2005).","journal-title":"Curr. Biol."},{"key":"3367_CR42","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","volume":"364","author":"WW Busse","year":"2011","unstructured":"Busse, W. W. et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N. Engl. J. Med. 364, 1005\u20131015 (2011).","journal-title":"N. Engl. J. Med"},{"key":"3367_CR43","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","volume":"136","author":"SJ Teach","year":"2015","unstructured":"Teach, S. J. et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J. Allergy Clin. Immunol. 136, 1476\u20131485 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"3367_CR44","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro, M. et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N. Engl. J. Med 378, 2486\u20132496 (2018).","journal-title":"N. Engl. J. Med"},{"key":"3367_CR45","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord, I. D. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380, 651\u2013659 (2012).","journal-title":"Lancet"},{"key":"3367_CR46","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel, E. H. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 371, 1189\u20131197 (2014).","journal-title":"N. Engl. J. Med"},{"key":"3367_CR47","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro, M., Zangrilli, J. & Wechsler, M. E. Corrections. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 3, e15 (2015).","journal-title":"Lancet Respir. Med"},{"key":"3367_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro, M. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 3, 355\u2013366 (2015).","journal-title":"Lancet Respir. Med"},{"key":"3367_CR49","first-page":"1205","volume":"377","author":"P Nair","year":"2017","unstructured":"Nair, P., Barker, P. & Goldman, M. Glucocorticoid Sparing of Benralizumab in Asthma. N. Engl. J. Med. 377, 1205 (2017).","journal-title":"N. Engl. J. Med"},{"key":"3367_CR50","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair, P. et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N. Engl. J. Med. 376, 2448\u20132458 (2017).","journal-title":"N. Engl. J. Med"},{"key":"3367_CR51","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/02770903.2017.1322611","volume":"55","author":"FC Albers","year":"2018","unstructured":"Albers, F. C. et al. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J. Asthma 55, 152\u2013160 (2018).","journal-title":"J. Asthma"},{"key":"3367_CR52","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/ni1247","volume":"6","author":"B Zhou","year":"2005","unstructured":"Zhou, B. et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat. Immunol. 6, 1047\u20131053 (2005).","journal-title":"Nat. Immunol."},{"key":"3367_CR53","doi-asserted-by":"crossref","unstructured":"Barlow, J. L. et al. IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J Allergy Clin Immunol. 132, 933\u2013941(2013).","DOI":"10.1016\/j.jaci.2013.05.012"},{"key":"3367_CR54","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1084\/jem.20122332","volume":"210","author":"SA Saenz","year":"2013","unstructured":"Saenz, S. A. et al. IL-25 simultaneously elicits distinct populations of innate lymphoid cells and multipotent progenitor type 2 (MPPtype2) cells. J. Exp. Med. 210, 1823\u20131837 (2013).","journal-title":"J. Exp. Med"},{"key":"3367_CR55","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","volume":"385","author":"ME Wechsler","year":"2021","unstructured":"Wechsler, M. E. et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N. Engl. J. Med. 385, 1656\u20131668 (2021).","journal-title":"N. Engl. J. Med"},{"key":"3367_CR56","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1164\/rccm.201312-2235OC","volume":"190","author":"R Djukanovic","year":"2014","unstructured":"Djukanovic, R. et al. The effect of inhaled IFN-beta on worsening of asthma symptoms caused by viral infections. A randomized trial. Am. J. Respir. Crit. Care Med 190, 145\u2013154 (2014).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"3367_CR57","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1086\/339339","volume":"185","author":"AG Mosser","year":"2002","unstructured":"Mosser, A. G. et al. Similar frequency of rhinovirus-infectible cells in upper and lower airway epithelium. J. Infect. Dis. 185, 734\u2013743 (2002).","journal-title":"J. Infect. Dis."},{"key":"3367_CR58","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00281-018-0701-1","volume":"40","author":"J Gunther","year":"2018","unstructured":"Gunther, J. & Seyfert, H. M. The first line of defence: insights into mechanisms and relevance of phagocytosis in epithelial cells. Semin Immunopathol. 40, 555\u2013565 (2018).","journal-title":"Semin Immunopathol."},{"key":"3367_CR59","doi-asserted-by":"publisher","first-page":"e1003531","DOI":"10.1371\/journal.ppat.1003531","volume":"9","author":"MM Zaiss","year":"2013","unstructured":"Zaiss, M. M. et al. IL-1beta suppresses innate IL-25 and IL-33 production and maintains helminth chronicity. PLoS Pathog. 9, e1003531 (2013).","journal-title":"PLoS Pathog."},{"key":"3367_CR60","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1182\/blood-2008-08-172767","volume":"113","author":"R Caruso","year":"2009","unstructured":"Caruso, R. et al. Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via p38 Map kinase-dependent induction of Socs-3. Blood 113, 3512\u20133519 (2009).","journal-title":"Blood"},{"key":"3367_CR61","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.4049\/jimmunol.1001758","volume":"185","author":"GE Kaiko","year":"2010","unstructured":"Kaiko, G. E., Phipps, S., Angkasekwinai, P., Dong, C. & Foster, P. S. NK cell deficiency predisposes to viral-induced Th2-type allergic inflammation via epithelial-derived IL-25. J. Immunol. 185, 4681\u20134690 (2010).","journal-title":"J. Immunol."},{"key":"3367_CR62","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1073\/pnas.97.2.773","volume":"97","author":"H Li","year":"2000","unstructured":"Li, H. et al. Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. Proc. Natl Acad. Sci. USA 97, 773\u2013778 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3367_CR63","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2017.04.025","volume":"46","author":"IE Galani","year":"2017","unstructured":"Galani, I. E. et al. Interferon-lambda Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness. Immunity 46, 875\u2013890 e876 (2017).","journal-title":"Immunity"},{"key":"3367_CR64","first-page":"1855","volume":"15","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. IL-25 promotes Th2 bias by upregulating IL-4 and IL-10 expression of decidual gammadeltaT cells in early pregnancy. Exp. Ther. Med 15, 1855\u20131862 (2018).","journal-title":"Exp. Ther. Med"},{"key":"3367_CR65","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1084\/jem.20051496","volume":"203","author":"AM Owyang","year":"2006","unstructured":"Owyang, A. M. et al. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J. Exp. Med 203, 843\u2013849 (2006).","journal-title":"J. Exp. Med"},{"key":"3367_CR66","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S1074-7613(01)00243-6","volume":"15","author":"MM Fort","year":"2001","unstructured":"Fort, M. M. et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15, 985\u2013995 (2001).","journal-title":"Immunity"},{"key":"3367_CR67","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4049\/jimmunol.169.1.443","volume":"169","author":"SD Hurst","year":"2002","unstructured":"Hurst, S. D. et al. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J. Immunol. 169, 443\u2013453 (2002).","journal-title":"J. Immunol."},{"key":"3367_CR68","doi-asserted-by":"crossref","unstructured":"Weathington, N. M. et al. IL-4 Induces the IL17Rb Gene Transcription in Monocytic Cells with Coordinate Autocrine IL-25 Signaling. Am. J. Respir. Cell Mol. Biol. 57, 346\u2013354 (2017).","DOI":"10.1165\/rcmb.2016-0316OC"},{"key":"3367_CR69","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1164\/rccm.200811-1730OC","volume":"180","author":"TL Hackett","year":"2009","unstructured":"Hackett, T. L. et al. Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-beta1. Am. J. Respir. Crit. Care Med 180, 122\u2013133 (2009).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"3367_CR70","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1183\/09031936.06.00130004","volume":"27","author":"C Boxall","year":"2006","unstructured":"Boxall, C., Holgate, S. T. & Davies, D. E. The contribution of transforming growth factor-beta and epidermal growth factor signalling to airway remodelling in chronic asthma. Eur. Respir. J. 27, 208\u2013229 (2006).","journal-title":"Eur. Respir. J."},{"key":"3367_CR71","doi-asserted-by":"publisher","first-page":"e44580","DOI":"10.1371\/journal.pone.0044580","volume":"7","author":"N Bedke","year":"2012","unstructured":"Bedke, N. et al. Transforming growth factor-beta promotes rhinovirus replication in bronchial epithelial cells by suppressing the innate immune response. PLoS ONE [Electron. Resour.] 7, e44580 (2012).","journal-title":"PLoS ONE [Electron. Resour.]"},{"key":"3367_CR72","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1634\/stemcells.2008-0171","volume":"26","author":"TL Hackett","year":"2008","unstructured":"Hackett, T. L. et al. Characterization of side population cells from human airway epithelium. Stem Cells 26, 2576\u20132585 (2008).","journal-title":"Stem Cells"},{"key":"3367_CR73","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ajpath.2011.10.036","volume":"180","author":"X Liu","year":"2012","unstructured":"Liu, X. et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am. J. Pathol. 180, 599\u2013607 (2012).","journal-title":"Am. J. Pathol."},{"key":"3367_CR74","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1165\/rcmb.2016-0276MA","volume":"56","author":"M Gentzsch","year":"2017","unstructured":"Gentzsch, M. et al. Pharmacological Rescue of Conditionally Reprogrammed Cystic Fibrosis Bronchial Epithelial Cells. Am. J. Respir. Cell Mol. Biol. 56, 568\u2013574 (2017).","journal-title":"Am. J. Respir. Cell Mol. Biol."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03367-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03367-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03367-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T08:53:12Z","timestamp":1669366392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-03367-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3367"],"URL":"https:\/\/doi.org\/10.1038\/s42003-022-03367-z","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,4]]},"assertion":[{"value":"28 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NWB reports grants, personal fees for consultancy and other (stock options) from Abeome Corporation\/Lanier Biotherapeutics during the conduct of the study; has a patent PCT WO2017160587A1. KA is an employee of Abeome Corporation and owns stock\/options in Abeome Corporation and Lanier Biotherapeutics. RAS reports personal fees for consultancy and owns stock\/options in Abeome Corporation and Lanier Biotherapeutics; has a patent PCT WO2017160587A1. CLJ is an employee of Lanier Biotherapeutics and owns stock\/options in Abeome Corporation and Lanier Biotherapeutics; has a patent PCT WO2017160587A1. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"415"}}